HUP9900681A2 - TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban - Google Patents

TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban

Info

Publication number
HUP9900681A2
HUP9900681A2 HU9900681A HUP9900681A HUP9900681A2 HU P9900681 A2 HUP9900681 A2 HU P9900681A2 HU 9900681 A HU9900681 A HU 9900681A HU P9900681 A HUP9900681 A HU P9900681A HU P9900681 A2 HUP9900681 A2 HU P9900681A2
Authority
HU
Hungary
Prior art keywords
ribavirin
activated
lymphocytes
modulation
analogs
Prior art date
Application number
HU9900681A
Other languages
English (en)
Inventor
Devron Averett
Kandasamy Ramasamy
Robert Tam
Original Assignee
Icn Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9900681(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Icn Pharmaceuticals, Inc. filed Critical Icn Pharmaceuticals, Inc.
Publication of HUP9900681A2 publication Critical patent/HUP9900681A2/hu
Publication of HUP9900681A3 publication Critical patent/HUP9900681A3/hu
Publication of HU220105B publication Critical patent/HU220105B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgyát eljárásők képezik nemvirális betegségben szenvedő,elfőjtőtt Th1-termeléssel és főkőzőtt Th2-termeléssel jellemezhetőcitőkinprőfillal rendelkező páciens kezelésére, tővábbá Th1- és Th2-válaszreakció befőlyásőlására emberi páciens aktivált T-sejtjeiben,Ribavirin alkalmazásával. A találmány szerinti megőldás előnyösenalkalmazható a limfőkinexpresszió instabilitásainak (egyensúlyiállapőttól való eltérésének) kezelésére, Ribavirin és Ribavirin-analógők felhasználásával. ŕ
HU9900681A 1996-01-23 1997-01-21 Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására HU220105B (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17
PCT/US1997/000600 WO1997026883A1 (en) 1996-01-23 1997-01-21 Modulation of th1/th2 cytokine expression by ribavirin® and ribavirin® analogs in activated t-lymphocytes

Publications (3)

Publication Number Publication Date
HUP9900681A2 true HUP9900681A2 (hu) 1999-07-28
HUP9900681A3 HUP9900681A3 (en) 1999-12-28
HU220105B HU220105B (hu) 2001-10-28

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900681A HU220105B (hu) 1996-01-23 1997-01-21 Ribavirin alkalmazása TH1- és TH2- válaszreakció befolyásolására szolgáló készítmények előállítására

Country Status (21)

Country Link
EP (1) EP0879056B1 (hu)
KR (1) KR100298158B1 (hu)
CN (1) CN1190198C (hu)
AT (1) ATE216886T1 (hu)
BR (1) BR9707154A (hu)
CA (1) CA2246162C (hu)
CZ (1) CZ293584B6 (hu)
DE (1) DE69712316T2 (hu)
DK (1) DK0879056T3 (hu)
ES (1) ES2172764T3 (hu)
HU (1) HU220105B (hu)
IL (1) IL125088A0 (hu)
NO (1) NO983372L (hu)
NZ (1) NZ330784A (hu)
PL (1) PL187439B1 (hu)
PT (1) PT879056E (hu)
RU (1) RU2186569C2 (hu)
SI (1) SI9720013A (hu)
SK (1) SK283342B6 (hu)
UA (1) UA46815C2 (hu)
WO (1) WO1997026883A1 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302474A1 (en) * 1996-10-16 2003-04-16 Ribapharm, Inc. Monocyclic L-nucleosides, analogs and uses thereof
ES2290969T3 (es) * 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
MXPA01007211A (es) * 1999-01-29 2002-05-06 Icn Pharmaceuticals Modulacion de la respuesta inmune por ribavirina.
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001290178A1 (en) 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
CN1599623B (zh) 2001-09-14 2011-05-11 赛托斯生物技术公司 免疫刺激物向病毒样颗粒内的包装:制备方法与用途
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
AU2007222135B2 (en) * 2006-03-09 2012-02-02 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
ES2427994T3 (es) 2006-06-12 2013-11-05 Cytos Biotechnology Ag Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN
EP2185195A2 (en) 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
PL2794627T3 (pl) 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
KR102327888B1 (ko) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU666852B2 (en) * 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases

Also Published As

Publication number Publication date
HU220105B (hu) 2001-10-28
EP0879056A1 (en) 1998-11-25
IL125088A0 (en) 1999-01-26
EP0879056A4 (en) 1999-01-13
KR19990081930A (ko) 1999-11-15
AU1747897A (en) 1997-08-20
PL187439B1 (pl) 2004-07-30
DK0879056T3 (da) 2002-08-19
CA2246162C (en) 2000-04-04
AU700642B2 (en) 1999-01-14
CA2246162A1 (en) 1997-07-31
BR9707154A (pt) 1999-05-25
ES2172764T3 (es) 2002-10-01
UA46815C2 (uk) 2002-06-17
HUP9900681A3 (en) 1999-12-28
PT879056E (pt) 2002-10-31
NO983372L (no) 1998-09-21
DE69712316D1 (en) 2002-06-06
SK100498A3 (en) 2001-03-12
CZ232998A3 (cs) 1999-04-14
SI9720013A (sl) 1999-06-30
NO983372D0 (no) 1998-07-22
DE69712316T2 (de) 2003-01-02
ATE216886T1 (de) 2002-05-15
KR100298158B1 (ko) 2001-09-06
RU2186569C2 (ru) 2002-08-10
CZ293584B6 (cs) 2004-06-16
PL328003A1 (en) 1999-01-04
SK283342B6 (sk) 2003-06-03
CN1190198C (zh) 2005-02-23
WO1997026883A1 (en) 1997-07-31
EP0879056B1 (en) 2002-05-02
NZ330784A (en) 1999-02-25
CN1209747A (zh) 1999-03-03

Similar Documents

Publication Publication Date Title
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
HUP0400689A2 (hu) ABCA-1 szint-emelő vegyületek
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
BR9910251A (pt) Estimulação hematopoiética
DE60239394D1 (de) Onkolytische virustherapie
ATE358176T1 (de) Menschliche dnase
DK184186D0 (da) Terapeutisk praeparat til behandling af virussygdomme
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
CY1112439T1 (el) Μεταλλαγμα fsh-γλυκοζυλιωσης
HK1055079A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
WO2002076313A8 (fr) Extenseur de l'os maxillaire
HUP0400340A2 (hu) Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
DE59704194D1 (de) Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
ATE499383T1 (de) Eine methode zur herstellung von menschlichem natürlichem interferon-alpha
DK383488A (da) Humant papillomavirus type 41, dets dna og deraf kodede proteiner
PT1077711E (pt) Tratamento de infeccao por virus do papiloma utilizando uma mycobacterium
ES2062502T3 (es) Una proteina de factor i pura y un procedimiento para obtener dicha proteina.
PT1150981E (pt) Composto nucleosidico terapeutico
IT1241993B (it) Uso di alfa-chetoglurato di arginina e/oppure di diarginina nella preparazione di composizioni farmaceutiche per il trattamento di deficit psicologici, immunologici e dell'apprendimento
NO894682D0 (no) Liggeunderlag til bruk i sykeseng for pasienter med liggesaar, brannsaar eller lignende.
UA30949A (uk) Спосіб комплексного лікування гнійно-запальних захворювань щелепно-лицьової області

Legal Events

Date Code Title Description
HPC4 Succession in title of patentee

Owner name: VALEANT RESEARCH & DEVELOPMENT, US

MM4A Lapse of definitive patent protection due to non-payment of fees